Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole

Infection with voriconazole-resistant fungi may become problematic, because organisms with decreased susceptibility have been noted. Breakthrough fungal infections occurred in 13 of 139 patients who received voriconazole at our center during the period of September 1998 through September 2003. Zygom...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2004-09, Vol.39 (5), p.743-746
Hauptverfasser:	Imhof, Alexander, Balajee, S. Arunmozhi, Fredricks, David N., Englund, Janet A., Marr, Kieren A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal agents Antifungals Aspergillosis Aspergillosis - drug therapy Aspergillus Aspergillus - drug effects Aspergillus - isolation & purification Azoles Bacterial diseases Bacterial sepsis Biological and medical sciences Brief Reports Candida glabrata Candida glabrata - drug effects Candida glabrata - metabolism Candida glabrata - physiology Candidiasis - drug therapy Candidiasis - metabolism Child Drug Resistance, Fungal - drug effects Drug Resistance, Fungal - physiology Female Fungal infections Fungemia - drug therapy Fungemia - metabolism Fungi Fungi - drug effects Fungi - isolation & purification Fungi - physiology Human bacterial diseases Human mycoses Humans Immunocompromised Host - physiology Infections Infectious diseases Lungs Male Medical sciences Microbial Sensitivity Tests Middle Aged Miscellaneous mycoses Mycoses Myeloid leukemia Pharmacology. Drug treatments Pyrimidines - therapeutic use Retrospective Studies Stem Cell Transplantation - adverse effects Transplantation Triazoles - therapeutic use Voriconazole Zygomycetes Zygomycosis - drug therapy Zygomycosis - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Infection with voriconazole-resistant fungi may become problematic, because organisms with decreased susceptibility have been noted. Breakthrough fungal infections occurred in 13 of 139 patients who received voriconazole at our center during the period of September 1998 through September 2003. Zygomycetes were found in 6 patients, and Candida glabrata bloodstream infection occurred in 4 patients. Minimal inhibitory concentrations were ⩾1 µg/mL for all available isolates. Yeasts and molds with decreased susceptibility to voriconazole may cause invasive infection in patients treated successfully for aspergillosis.
ISSN:	1058-4838 1537-6591
DOI:	10.1086/423274